about
The eNanoMapper database for nanomaterial safety informationThe ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity TestingComputational toxicology using the OpenTox application programming interface and BioclipseCollaborative development of predictive toxicology applications.OpenTox predictive toxicology framework: toxicological ontology and semantic media wiki-based OpenToxipedia.Cancer Biology, Toxicology and Alternative Methods Development Go Hand-in-HandA European perspective on alternatives to animal testing for environmental hazard identification and risk assessmentRapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience.Toxicology ontology perspectives.Toxicogenomics directory of chemically exposed human hepatocytes.Collaborative virtual organisation and infrastructure for drug discovery.Food for thought ... A toxicology ontology roadmap.Growing significance of communities and collaboration in discovery and development.Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure.CompNanoTox2015: novel perspectives from a European conference on computational nanotoxicology on predictive nanotoxicology.The SEURAT-1 approach towards animal free human safety assessment.Chapter 11. Computational Modelling of Biological Responses to Engineered NanomaterialsIn silico toxicology protocols.Interactive predictive toxicology with Bioclipse and OpenToxAdvanced tools for the safety assessment of nanomaterialsSharing dose response data and analysis across the SEURAT-1 clusterThe eNanoMapper database for nanomaterial safety informationIntegrated analysis of in vitro data and the adverse outcome pathway framework for prioritization and regulatory applications: An exploratory case study using publicly available data on piperonyl butoxide and liver modelsIntegrated analysis of in vitro data and the adverse outcome pathway framework for prioritization and regulatory applications: An exploratory case study using publicly available data on piperonyl butoxide and liver models
P50
Q24188395-BE5D91BF-D424-4F30-A839-2E9D1EEBEA7CQ27062617-7D6E676E-A015-4156-AE7C-E47F55F2A836Q27134787-D8284242-EB1B-4D39-A18E-0EFAF42DC813Q27162585-7BE45901-E29A-4FE4-AFBD-12120DB5A473Q27921857-246C0FAC-A981-4286-98C0-DCDB2BEC70CDQ28549191-4FE3B4CC-9EA5-4521-9617-DB33A78704A7Q28651094-B4036606-B76B-45DB-A9DB-63C5A3A85649Q33459146-5B7F12C5-E6A6-4276-AE52-8DB2C21A3254Q34273133-246BF59E-D2E9-4A81-8E4F-D7289BBBA66FQ35423042-2954ED20-A210-4520-AB9A-E8464942C1F6Q38410280-7C9B0029-E963-4B9A-AA4D-239CFBD054EEQ38497242-9898CADA-C19F-4995-A026-4807229EF49CQ39975589-FE89AF0C-D203-4DAE-B24F-B8F9BC6FA8BDQ45951535-35532282-DD72-43EE-A8C0-1858FCFBAF18Q47694615-6DA30077-ED59-440B-824F-5B85C7E3D4EEQ51037430-9F71261F-CD17-4F66-B1AB-CB5166F32E5CQ52263552-381fd797-4976-ddb7-3ded-ab52858cd1d8Q52263552-E591BC59-140C-4ABF-9526-075708671491Q52573546-581F5629-89DF-4861-8B25-F12BF5F31FD3Q54405113-B0CB7476-D2EF-48F3-A2BE-075DEA406C77Q55401914-81D65D39-FC93-4BF8-970D-0F6ECC379693Q56160807-F8046CF8-93CB-4BA7-9303-AB4F97D7C988Q56919959-144D99D2-8EA5-42E2-AA6F-D370716B71DBQ56976500-62B29495-A5FA-410A-A7A8-D5312E7BFEF9Q57159884-F15D6BAA-E8C0-4D06-A3F8-D55B30C64B69
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Barry Hardy
@ast
Barry Hardy
@en
Barry Hardy
@es
Barry Hardy
@nl
Barry Hardy
@sl
type
label
Barry Hardy
@ast
Barry Hardy
@en
Barry Hardy
@es
Barry Hardy
@nl
Barry Hardy
@sl
altLabel
B Hardy
@en
prefLabel
Barry Hardy
@ast
Barry Hardy
@en
Barry Hardy
@es
Barry Hardy
@nl
Barry Hardy
@sl